Camargopharma.com / Prescription drugs
Domain overview in Prescription Drugs niche. Based on relevant links and pages only.
| camargopharma.com rank 243 |
| Number of domains linking to camargopharma.com 1 | semantic flow 0.08 |
| Number of links to camargopharma.com 1 | semantic flow 0.08 |
| Number of domains linked from camargopharma.com 18 | semantic flow 2.5 |
| Number of links from camargopharma.com 45 | semantic flow 2.5 |
Popular pages pointing to camargopharma.com
Pages with highest topical PageRank pointing to domain.
Popular pages from camargopharma.com
On-topic pages from domain with highest topical PageRank.
| title / url |  | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| Extrapolation of Clinical Data for Pediatric Uses: Application for Medical Devices and Drug Products | Camargo https://camargopharma.com/2016/10/extrapolation-of-clinical-data-for-pediatric-uses-applic  | 0.28 | 0.71 | 57 | 14 | 4 | 2 | 0 | 0 | |
| Due Diligence Assessment: Determining a Drug Productu2019s Potential Value | Camargo https://camargopharma.com/2017/05/due-diligence-assessment-determining-a-drug-products-val | 0.28 | 0.52 | 60 | 12 | 1 | 1 | 0 | 0 | |
| Referencing a Listed Drug for the 505(b)(2) Pathway | Camargo https://camargopharma.com/2017/02/referencing-listed-drug-505b2-pathway/ | 0.28 | 1 | 60 | 15 | 3 | 2 | 0 | 0 | |
| Demystifying Orange Book Designations: The New Referencing Approved Drug Products in ANDA Submissions Draft Guidance | Camargo https://camargopharma.com/2017/02/demystifying-orange-book-designations-new-referencing-ap | 0.21 | 0.99 | 62 | 17 | 3 | 2 | 0 | 0 | |
| Generic or 505(b)(2)? | Camargo https://camargopharma.com/2009/11/generic-or-505b2/ | 0.21 | 0.94 | 55 | 10 | 1 | 1 | 0 | 0 | |
| Leveraging Postmarketing Safety Data in 505(b)(2) Drug Development Programs | Camargo https://camargopharma.com/2016/08/leveraging-postmarketing-safety-data-505b2-drug-developm | 0.21 | 0.89 | 58 | 11 | 1 | 1 | 0 | 0 | |
| Is a Reference Listed Drug Mandatory in the 505(b)(2) Pathway? | Camargo https://camargopharma.com/2016/03/reference-listed-drug-mandatory-505b2-pathway/ | 0.19 | 0.93 | 54 | 12 | 1 | 1 | 0 | 0 |
Domains with most semantic flow to camargopharma.com
Relevant domains with most links to selected domain.
| domain | | | |
|---|---|---|---|
| http://npr.org/ | 1 | 0.08 | npr.org |
Domains with most semantic flow from camargopharma.com
Relevant domains with most links from selected domain.
Most linked pages from camargopharma.com
Pages from domain with most relevant inbound links.
| url | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| https://camargopharma.com/about-us/ | 1 | 0.15 | 0.92 | 0.08 | 0.96 | yes | 34 | 8 | 0 | 0 | 1 | 1 | |
| https://camargopharma.com/?s=prodrug | 1 | 0.17 | 0.94 | 0.07 | -1 | - | -1 | -1 | -1 | -1 | 0 | 0 | |
| https://camargopharma.com/services/feasibility/ | 1 | 0.17 | 0.98 | 0.07 | 0.66 | yes | 30 | 4 | 0 | 0 | 0 | 0 | |
| https://camargopharma.com/services/ | 1 | 0.17 | 0.97 | 0.07 | -1 | no | -1 | -1 | -1 | -1 | 0 | 0 | |
| https://camargopharma.com/ | 1 | 0.17 | 0.17 | 0.07 | -1 | no | -1 | -1 | -1 | -1 | 0 | 0 | |
| https://camargopharma.com/?s=DESI | 1 | 0.17 | 0.94 | 0.07 | -1 | - | -1 | -1 | -1 | -1 | 0 | 0 | |
| https://camargopharma.com/?s=OTC | 1 | 0.17 | 0.93 | 0.07 | -1 | - | -1 | -1 | -1 | -1 | 0 | 0 | |
| https://camargopharma.com/services/complex-generics-services/ | 1 | 0.17 | 0.85 | 0.06 | 0.7 | yes | 29 | 5 | 0 | 0 | 0 | 0 | |
| https://camargopharma.com/2017/11/how-will-new-fda-guidance-for-generic-abuse-deterrent-op | 1 | 0.17 | 0.8 | 0.05 | 0.89 | yes | 56 | 12 | 2 | 2 | 0 | 0 | |
| https://camargopharma.com/services/clinical-studies-phases-i-iv/ | 1 | 0.17 | 0.95 | 0.03 | -1 | no | -1 | -1 | -1 | -1 | 0 | 0 |
Hubs from camargopharma.com
Pages from domain with most likely on-topic outgoing links.
| url | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| https://camargopharma.com/category/desi-drug/ | 15 | 0.17 | 0.97 | 1.2 | 0.99 | yes | 53 | 19 | 0 | 0 | 0 | 0 | |
| https://camargopharma.com/2016/08/abuse-deterrence-labeling-generic-vs-505b2-drug-developm | 10 | 0.17 | 0.91 | 0.16 | 0.62 | yes | 66 | 18 | 10 | 9 | 0 | 0 | |
| https://camargopharma.com/about-us/ | 8 | 0.15 | 0.92 | 0.5 | 0.96 | yes | 34 | 8 | 0 | 0 | 1 | 1 | |
| https://camargopharma.com/category/orphan-drug/ | 7 | 0.17 | 0.96 | 0.55 | 1 | yes | 46 | 11 | 0 | 0 | 0 | 0 | |
| https://camargopharma.com/2017/11/how-will-new-fda-guidance-for-generic-abuse-deterrent-op | 7 | 0.17 | 0.8 | 0.35 | 0.89 | yes | 56 | 12 | 2 | 2 | 0 | 0 | |
| https://camargopharma.com/2016/08/orphan-drug-development-ensuring-best-time-market/ | 6 | 0.17 | 0.97 | 0.44 | 0.97 | yes | 61 | 16 | 3 | 2 | 0 | 0 | |
| https://camargopharma.com/2011/03/what-is-the-pediatric-drug-development-approach-for-rare | 1 | 0.17 | 0.97 | 0.08 | 0.99 | yes | 57 | 12 | 1 | 1 | 0 | 0 | |
| https://camargopharma.com/services/complex-generics-services/ | 1 | 0.17 | 0.85 | 0.04 | 0.7 | yes | 29 | 5 | 0 | 0 | 0 | 0 | |
| https://camargopharma.com/2016/11/expedited-approval-australia/ | 1 | 0.17 | 0.91 | 0.02 | -1 | no | -1 | -1 | -1 | -1 | 0 | 0 | |
| https://camargopharma.com/services/clinical-studies-phases-i-iv/ | 1 | 0.17 | 0.95 | 0 | -1 | no | -1 | -1 | -1 | -1 | 0 | 0 |
Similar domains to camargopharma.com
Similar domains to domain, based on inbound linking patterns from other relevant domains. This is also known in SEO as topical co-citation.